States

This section of the Rural Health Toolkit includes examples of innovative telehealth approaches to provide care for people with opioid use disorder in rural communities.

This Guide provides concrete strategies and actions for hospitals and health systems seeking to implement, strengthen and sustain telebehavioral health programs.

This whitepaper examines telehealth risks utilizing the eight American Society for Health Care Risk Management (ASHRM) enterprise risk management (ERM) domains.

An informational page on the Bloomberg American Health Initiative website which details facts and resources from their Fentanyl Overdose Reduction Checking Analysis Study (FORECAST).

This brief describes research documenting the added challenges stimulant use contributes to those who use opioids and patient-centered approaches for working with people who use stimulants that are enrolled in medication treatment for opioid use disorder.

This brief reviews opioid and stimulant trends in availability, use, and impacts; compares opioids and stimulants in terms of drug effects and motivations for use; and examines the factors that drive co-use.

This guide describes relevant research findings, examines best practices, identifies knowledge gaps and implementation challenges, and offers useful resources for treating stimulant use disorders.

This toolkit offers high-level strategies for integrating The American Society of Addiction Medicine Criteria into a state’s approach to SUD services, as well as potential pathways, implementation vehicles, state examples, model legislative, regulatory, and contractual language.

This guide provides considerations and strategies for clinicians and organizations implementing evidence-based practices. Approaches presented will assist clinicians, behavioral health organizations, primary care providers, insurers, and policy makers in understanding, selecting, and implementing evidence-based interventions that support adults with concurrent substance use and/or concurrent substance use disorders, including alcohol.

This brief explores COVID-19 policy changes related to access to medications for opioid use disorder and recommends changes to keep in place beyond the emergency period.